One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma

Timothy W. Corson, Brenda L. Gallie

Research output: Contribution to journalReview article

165 Citations (Scopus)

Abstract

The childhood eye cancer retinoblastoma is initiated by the loss of both alleles of the prototypic tumor suppressor gene, RBI. However, a large number of cytogenetic and comparative genomic hybridization (CGH) studies have shown that these MI and M2 mutational events - although necessary for initiation - are not the only genomic changes in retinoblastoma. Some of these subsequent changes, which we have termed M3 to Mn, are likely crucial for tumor progression not only in retinoblastoma but also in other cancers. Moreover, genes showing genomic change in cancer are more stable markers and, therefore, possible therapeutic targets than genes simply differentially expressed. In this review, we provide the first comprehensive summary of the genomic evidence implicating gain of 1q, 2p, 6p, and 13q, and loss of 16q in retinoblastoma oncogenesis, including karyotype, CGH, and microarray CGH data. We discuss the search for candidate oncogenes and tumor suppressor genes within these regions, including the candidates (KIF14, MDM14, MYCN, E2F3, DEK, CDH11, and others), plus associations between genomic changes and clinical parameters. We also review studies of other regions of the retinoblastoma genome, the epigenetic changes of aberrant methylation of MGMT, RASSFIA, CASP8, and MLHI, and the roles microRNAs might play in this cancer. Although many candidate genes have yet to be functionally validated in retinoblastoma, work in this field lays out a molecular cytogenetic pathway of retinoblastoma development. Candidate cancer genes carry diagnostic, prognostic, and therapeutic implications beyond retinoblastoma.

Original languageEnglish (US)
Pages (from-to)617-634
Number of pages18
JournalGenes Chromosomes and Cancer
Volume46
Issue number7
DOIs
StatePublished - Jul 1 2007

Fingerprint

Retinoblastoma
Comparative Genomic Hybridization
Tumor Suppressor Genes
Cytogenetics
Neoplasms
Genes
Neoplasm Genes
MicroRNAs
Karyotype
Oncogenes
Epigenomics
Methylation
Carcinogenesis
Alleles
Genome
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. / Corson, Timothy W.; Gallie, Brenda L.

In: Genes Chromosomes and Cancer, Vol. 46, No. 7, 01.07.2007, p. 617-634.

Research output: Contribution to journalReview article

@article{c052ad109d1a40e4b183b2f4304dc1ea,
title = "One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma",
abstract = "The childhood eye cancer retinoblastoma is initiated by the loss of both alleles of the prototypic tumor suppressor gene, RBI. However, a large number of cytogenetic and comparative genomic hybridization (CGH) studies have shown that these MI and M2 mutational events - although necessary for initiation - are not the only genomic changes in retinoblastoma. Some of these subsequent changes, which we have termed M3 to Mn, are likely crucial for tumor progression not only in retinoblastoma but also in other cancers. Moreover, genes showing genomic change in cancer are more stable markers and, therefore, possible therapeutic targets than genes simply differentially expressed. In this review, we provide the first comprehensive summary of the genomic evidence implicating gain of 1q, 2p, 6p, and 13q, and loss of 16q in retinoblastoma oncogenesis, including karyotype, CGH, and microarray CGH data. We discuss the search for candidate oncogenes and tumor suppressor genes within these regions, including the candidates (KIF14, MDM14, MYCN, E2F3, DEK, CDH11, and others), plus associations between genomic changes and clinical parameters. We also review studies of other regions of the retinoblastoma genome, the epigenetic changes of aberrant methylation of MGMT, RASSFIA, CASP8, and MLHI, and the roles microRNAs might play in this cancer. Although many candidate genes have yet to be functionally validated in retinoblastoma, work in this field lays out a molecular cytogenetic pathway of retinoblastoma development. Candidate cancer genes carry diagnostic, prognostic, and therapeutic implications beyond retinoblastoma.",
author = "Corson, {Timothy W.} and Gallie, {Brenda L.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1002/gcc.20457",
language = "English (US)",
volume = "46",
pages = "617--634",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma

AU - Corson, Timothy W.

AU - Gallie, Brenda L.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - The childhood eye cancer retinoblastoma is initiated by the loss of both alleles of the prototypic tumor suppressor gene, RBI. However, a large number of cytogenetic and comparative genomic hybridization (CGH) studies have shown that these MI and M2 mutational events - although necessary for initiation - are not the only genomic changes in retinoblastoma. Some of these subsequent changes, which we have termed M3 to Mn, are likely crucial for tumor progression not only in retinoblastoma but also in other cancers. Moreover, genes showing genomic change in cancer are more stable markers and, therefore, possible therapeutic targets than genes simply differentially expressed. In this review, we provide the first comprehensive summary of the genomic evidence implicating gain of 1q, 2p, 6p, and 13q, and loss of 16q in retinoblastoma oncogenesis, including karyotype, CGH, and microarray CGH data. We discuss the search for candidate oncogenes and tumor suppressor genes within these regions, including the candidates (KIF14, MDM14, MYCN, E2F3, DEK, CDH11, and others), plus associations between genomic changes and clinical parameters. We also review studies of other regions of the retinoblastoma genome, the epigenetic changes of aberrant methylation of MGMT, RASSFIA, CASP8, and MLHI, and the roles microRNAs might play in this cancer. Although many candidate genes have yet to be functionally validated in retinoblastoma, work in this field lays out a molecular cytogenetic pathway of retinoblastoma development. Candidate cancer genes carry diagnostic, prognostic, and therapeutic implications beyond retinoblastoma.

AB - The childhood eye cancer retinoblastoma is initiated by the loss of both alleles of the prototypic tumor suppressor gene, RBI. However, a large number of cytogenetic and comparative genomic hybridization (CGH) studies have shown that these MI and M2 mutational events - although necessary for initiation - are not the only genomic changes in retinoblastoma. Some of these subsequent changes, which we have termed M3 to Mn, are likely crucial for tumor progression not only in retinoblastoma but also in other cancers. Moreover, genes showing genomic change in cancer are more stable markers and, therefore, possible therapeutic targets than genes simply differentially expressed. In this review, we provide the first comprehensive summary of the genomic evidence implicating gain of 1q, 2p, 6p, and 13q, and loss of 16q in retinoblastoma oncogenesis, including karyotype, CGH, and microarray CGH data. We discuss the search for candidate oncogenes and tumor suppressor genes within these regions, including the candidates (KIF14, MDM14, MYCN, E2F3, DEK, CDH11, and others), plus associations between genomic changes and clinical parameters. We also review studies of other regions of the retinoblastoma genome, the epigenetic changes of aberrant methylation of MGMT, RASSFIA, CASP8, and MLHI, and the roles microRNAs might play in this cancer. Although many candidate genes have yet to be functionally validated in retinoblastoma, work in this field lays out a molecular cytogenetic pathway of retinoblastoma development. Candidate cancer genes carry diagnostic, prognostic, and therapeutic implications beyond retinoblastoma.

UR - http://www.scopus.com/inward/record.url?scp=34249004558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249004558&partnerID=8YFLogxK

U2 - 10.1002/gcc.20457

DO - 10.1002/gcc.20457

M3 - Review article

C2 - 17437278

AN - SCOPUS:34249004558

VL - 46

SP - 617

EP - 634

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 7

ER -